

Appln No.: 10/646,391
Amendment Dated: April 5, 2007
Response to Office Action dated March 28, 2007

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (canceled)
2. (previously presented) The method of claim 14, wherein the therapeutic agent is an antisense oligodeoxynucleotide.
3. (original) The method of claim 2, wherein the antisense oligodeoxynucleotide spans either the translation initiation site or the termination site.
4. (original) The method of claim 3, wherein the antisense oligodeoxynucleotide is modified to enhance in vivo stability relative to an unmodified oligodeoxynucleotide of the same sequence.
5. (previously presented) The method of claim 4, wherein the modification is a 2'-O-(2-methoxyethyl) modification.
6. (original) The method of claim 5, wherein the antisense oligodeoxynucleotide consists essentially of an oligodeoxynucleotide selected from the group consisting of Seq. ID. Nos. 2 to 19.
7. (original) The method of claim 6, wherein the antisense oligodeoxynucleotide consists essentially of an oligodeoxynucleotide consisting of Seq. ID. No. 4.

Appln No.: 10/646,391
Amendment Dated: April 5, 2007
Response to Office Action dated March 28, 2007

8. (original) The method of claim 7, wherein the oligonucleotide has a phosphorothioate backbone throughout, the sugar moieties of nucleotides 1-4 and 18-21, the "wings", bear 2'-O-methoxyethyl modifications and the remaining nucleotides are 2'-deoxynucleotides.

9. (original) The method of claim 2, wherein the antisense oligodeoxynucleotide consists essentially of an oligodeoxynucleotide selected from the group consisting of Seq. ID. Nos. 2 to 19.

10. (previously presented) The method of claim 9, wherein the antisense oligodeoxynucleotide consists essentially of an oligodeoxynucleotide consisting of Seq. ID. No. 4.

11. (previously presented) The method of claim 14, wherein the therapeutic agent is an RNA molecule effective to reduce the amount of clusterin in the melanoma cells by an RNAi mechanism.

12. (original) The method of claim 11, wherein the RNA molecule consists essentially of an oligodeoxynucleotide selected from the group consisting of Seq. ID. Nos. 20 to 25.

13. (canceled)

14. (currently amended) A method for treatment of melanoma in a mammalian subject, comprising the step of administering to the subject a therapeutic agent effective to reduce the amount of clusterin in the melanoma cells, wherein the therapeutic agent is an oligonucleotide targeted to clusterin.